Przemysław R Kac, Fernando González-Ortiz, Andreja Emeršič, Maciej Dulewicz, Srinivas Koutarapu, Michael Turton, Yang An, Denis Smirnov, Agnieszka Kulczyńska-Przybik, Vijay R Varma, Nicholas J Ashton, Laia Montoliu-Gaya, Elena Camporesi, Izabela Winkel, Bogusław Paradowski, Abhay Moghekar, Juan C Troncoso, Tammaryn Lashley, Gunnar Brinkmalm, Susan M Resnick, Barbara Mroczko, Hlin Kvartsberg, Milica Gregorič Kramberger, Jörg Hanrieder, Saša Čučnik, Peter Harrison, Henrik Zetterberg, Piotr Lewczuk, Madhav Thambisetty, Uroš Rot, Douglas Galasko, Kaj Blennow, Thomas K Karikari
Blood phosphorylated tau (p-tau) biomarkers, including p-tau217, show high associations with Alzheimer's disease (AD) neuropathologic change and clinical stage. Certain plasma p-tau217 assays recognize tau forms phosphorylated additionally at threonine-212, but the contribution of p-tau212 alone to AD is unknown. We developed a blood-based immunoassay that is specific to p-tau212 without cross-reactivity to p-tau217. Here, we examined the diagnostic utility of plasma p-tau212. In five cohorts (n = 388 participants), plasma p-tau212 showed high performances for AD diagnosis and for the detection of both amyloid and tau pathology, including at autopsy as well as in memory clinic populations...
March 23, 2024: Nature Communications